Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05766267 · ClinicalTrials.gov registry record · Phase 2
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
A Phase 2 study of Tuberculosis, Pulmonary and Tuberculosis Infection, sponsored by Centers for Disease Control and Prevention.
- Active
- Registry status
- Phase 2
- Development phase
- 288
- Enrollment target
- 8
- Study locations
NCT05766267: Active Phase 2 study of Tuberculosis, Pulmonary and Tuberculosis Infection, sponsored by Centers for Disease Control and Prevention.
NCT05766267 is a Phase 2 study of Tuberculosis, Pulmonary and Tuberculosis Infection that is active but no longer recruiting, run by Centers for Disease Control and Prevention. The registered enrollment target is 288 participants, above the 66-participant average among 3 other Tuberculosis, Pulmonary trials with a reported enrollment target (336% higher). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05766267, a Phase 2 study of Tuberculosis, Pulmonary and Tuberculosis Infection, is active but no longer recruiting, sponsored by Centers for Disease Control and Prevention.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 288 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine whether one or two 17-week regimens of tuberculosis treatment bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ) plus either Rifabutin (Rb) or Delamanid (D or DLM) are as effective as a standard six-month regimen for treatment of pulmonary tuberculosis (TB). All three regimens are administered daily, seven days each week. The first 17-week regimen is 2 months of bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) plus rifabutin (Rb) (BMZRB) followed by 2 months of bedaquiline (B or BDQ), moxifloxacin (M) and Rifabutin (Rb) (2 BMZRb/2 BMRb, Arm 1) The Second 17-week regimen is 2 months of bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) plus delamanid (D or DLM); (BMZD) followed by 2 months of bedaquiline (B or BDQ), moxifloxacin (M) and delamanid (D or DLM) (2 BMZD/2 BMD, Arm 2) The standard 26-week treatment control regimen which is two months of isoniazid, rifampin, ethambutol, and pyrazinamide (2HRZE) followed by four months of isoniazid and rifampin (4HR); (2HRZE/4HR, Arm 3) Target enrollment is 288 male and female participants (96/arm). participants. Participants will be followed until 78 weeks post-randomization, or until the last enrolled participant completes 52 weeks post-randomization, whichever comes first.
Primary Outcome
The purpose of this study is to determine whether one or two 17-week regimens of tuberculosis treatment bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ) plus either Rifabutin (Rb) or Delamanid (D or DLM) are as effective as a standard six-month regimen for treatment of pulmonary tuberculosis (TB). All three regimens are administered daily, seven days each week. The time to culture negative will be defined as the time from randomization to the date of the first of at least two c
Conditions Studied
Interventions
- DRUG Moxifloxacin
- DRUG Rifabutin
- DRUG Delamanid
- DRUG Bedaquiline
- DRUG Pyrazinamide
Study Locations (8)
Other
- McGill University Health Centre - Montreal
- Vancouver, British Columbia Centre for Disease Control - Vancouver
- TBTC Site 30 Uganda-Case Western Reserve Research Collaboration - Kampala
Ouest
- TBTC Site 67 GHESKIO centers IMIS - Port-au-Prince
- TBTC Site 45 Les Centres Gheskio (INLR) - Port-au-Prince
Washington
- TBTC Site 26 Seattle & King County TB Control Program - Seattle
Cape Town
- TBTC Site 09 University of Cape Town Lung Institute (Pty) Ltd - Mowbray
Can Tho City
- TBTC Site 76 CAB-V. Can Tho Province, Vietnam - Thot Not District TB Unit - Can Tho
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2023-11-21 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What the registry record for NCT05766267 still lists
NCT05766267 is an interventional study that assigns participants to a tested intervention. The registered 288 participants enrollment target is mid-sized for trials with a published cap, above the 66-participant average among 3 other Tuberculosis, Pulmonary trials with a reported enrollment target (336% higher).
The record links to 2 conditions, with Tuberculosis, Pulmonary appearing as the primary indexed condition, and to 5 interventions - of which Moxifloxacin is the first listed.
NCT05766267 lists 8 locations in 5 states (Other, Ouest, Washington).
Frequently Asked Questions
What is clinical trial NCT05766267 about?
NCT05766267 is a clinical study titled "Short-course Regimens for the Treatment of Pulmonary Tuberculosis". The purpose of this study is to determine whether one or two 17-week regimens of tuberculosis treatment bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ) plus either Rifabutin (Rb) or Delamanid (D or DLM) are as effective as a standard six-month regimen for treatment of pulmonary tu...
What is the current status of trial NCT05766267?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 288 participants. The study started on 2023-11-21. Estimated completion is 2027-12-31.
What conditions does trial NCT05766267 study?
This clinical trial studies the following conditions: Tuberculosis, Pulmonary, Tuberculosis Infection.
What interventions are being tested in trial NCT05766267?
The interventions under investigation include: Moxifloxacin (DRUG), Rifabutin (DRUG), Delamanid (DRUG), Bedaquiline (DRUG), Pyrazinamide (DRUG).
Who is sponsoring clinical trial NCT05766267?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05766267 being conducted?
This trial has 8 study locations across Washington, Ouest, Cape Town, Can Tho City. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tuberculosis, Pulmonary
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
- NCT03741777 · 288 participants · NA
Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume
- NCT03937635 · 288 participants · Phase 3
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- NCT04621877 · 288 participants · NA
Lay-Delivered Behavioral Activation in Senior Centers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI